Pyrethrins + Piperonyl Butoxide + N-Octyl Bicyclopheptene Dicarboximide

Verify with FDA CVM →

25 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
25
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Pyrethrins + Piperonyl Butoxide + N-Octyl Bicyclopheptene Dicarboximide

Administration Routes

CutaneousTopicalUnknownAuricular (Otic)

Species Affected

Dog 22
Cat 3

Most Affected Breeds

Dachshund (unspecified) 5
Domestic Shorthair 2
Terrier - Jack Russell 2
Chihuahua 2
Maltese 1
Terrier - West Highland White 1
Rottweiler 1
Brittany 1
Dachshund - Miniature 1
Crossbred Canine/dog 1

Most Reported Reactions

Lack of efficacy (ectoparasite) - flea 11
Lack of efficacy (flea) 5
Itching 3
Lack of efficacy - NOS 3
Emesis 2
Shaking 2
Anaphylactoid reaction 2
Vomiting 2
Cough 1
Overdose 1
Trembling 1
Eye disorder NOS (for photophobia see 'neurological') 1

Outcome Breakdown

Outcome Unknown
13 (52.0%)
Recovered/Normal
8 (32.0%)
Ongoing
4 (16.0%)

Data Summary

Metric Value
Total adverse event reports 25
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 18
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Pyrethrins + Piperonyl Butoxide + N-Octyl Bicyclopheptene Dicarboximide Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 25 adverse event reports referencing Pyrethrins + Piperonyl Butoxide + N-Octyl Bicyclopheptene Dicarboximide, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Pyrethrins + Piperonyl Butoxide + N-Octyl Bicyclopheptene Dicarboximide. Reported administration routes include Cutaneous, Topical, Unknown, Auricular (Otic). These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Pyrethrins + Piperonyl Butoxide + N-Octyl Bicyclopheptene Dicarboximide reports are Dog (22 reports), Cat (3 reports), with Dog accounting for the largest share. Within those species, Dachshund (unspecified) (5), Domestic Shorthair (2), Terrier - Jack Russell (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Pyrethrins + Piperonyl Butoxide + N-Octyl Bicyclopheptene Dicarboximide are Lack of efficacy (ectoparasite) - flea (11), Lack of efficacy (flea) (5), Itching (3), Lack of efficacy - NOS (3). Of the 25 reports with a coded outcome, Outcome Unknown is the leading category at 52.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Pyrethrins + Piperonyl Butoxide + N-Octyl Bicyclopheptene Dicarboximide.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial